IN THE CLAIMS

1. (original) A compound of the formula



I

wherein R^1 is fluoro;

s is three;

R^2 is $(C_1\text{-}C_6)$alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, $(C_1\text{-}C_6)$alkyl, hydroxy, $(C_1\text{-}C_6)$alkoxy, and $(C_1\text{-}C_6)$alkyl-(C=O)-O-;

or a pharmaceutically acceptable salt thereof.

2. (original) A compound according to claim 1 wherein R^2 is $(C_1\text{-}C_6)$alkyl optionally substituted with one or two groups independently selected from halo, hydroxy, and $(C_1\text{-}C_6)$alkoxy.

3. (original) A compound according to claim 1, wherein R^2 is optionally substituted ethyl, isopropyl, isobutyl, t-butyl or sec-butyl.

4. (original) A compound according to claim 1, wherein the compound has the formula



Ia

5. (original) A compound according to claim 1, wherein R^2 is $(C_1\text{-}C_6)$alkyl, optionally substituted with halo or hydroxy.

6. (original) A compound according to claim 1, wherein R^2 is ethyl, isopropyl, isobutyl, t-butyl or sec-butyl; optionally substituted with a halo or hydroxy.

7. (original) A compound according to claim 1, wherein R^2 is $(C_1\text{-}C_4)$alkyl.

8. (original) A compound according to claim 1, wherein said compound is 3-Isopropyl-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

9. (original) A compound according to claim 1, wherein said compound is 3-tert-Butyl-6-[4-(2,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

10. (original) A compound according to claim 1, wherein said compound is selected from the group consisting of:

3-Isopropyl-6-[4-(2,3,4-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;

3-Isopropyl-6-[4-(2,3,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine;

3-Isopropyl-6-[4-(2,4,6-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine; and

3-Isopropyl-6-[4-(3,4,5-trifluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo[4,3-a]pyridine.

11. (withdrawn) A method of treating an MAP kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

12. (withdrawn) A method of treating a p38 kinase mediated disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound according to claim 1.

13. (withdrawn) A method for treating a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human, comprising administering to said mammal an amount of a compound according to claim 1 effective in treating such a condition.

14. (amended) A pharmaceutical ~~**composition for the treatment of a condition selected from the group consisting of arthritis, psoriatic arthritis, Reiter's syndrome, rheumatoid arthritis, gout, traumatic arthritis, rubella arthritis and acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and**~~

~~other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, Alzheimer's disease, stroke, neurotrauma, asthma, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, osteoporosis, restenosis, cardiac and renal reperfusion injury, thrombosis, glomerularonephritis, diabetes, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, muscle degeneration, eczema, contact dermatitis, psoriasis, sunburn, and conjunctivitis shock in a mammal, including a human,~~ comprising an amount of a compound according to claim 1 ~~effective in such treatment~~ and a pharmaceutically acceptable carrier.

15. (Canceled)

16. (Canceled)